Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
454 Life Sciences
Data presented on ultra-deep sequencing of HIV virus
July 6th, 2005
454 Life Sciences, a majority-owned subsidiary of CuraGen Corporation (CRGN), reported that scientists from the company presented a poster detailing a potentially new application for the company's technology - ultra-deep sequencing of the HIV virus. The poster, in addition to an oral presentation on Friday, June 10, at the XIV International HIV Drug Resistance Workshop in Quebec City, Quebec, Canada, discusses the ability of 454's sequencing platform to rapidly, reproducibly and accurately detect minor HIV variants that contain drug resistance mutations present in HIV-infected patients. Identifying and understanding HIV drug resistance is necessary...
Source: Biotech Week (2005-07-06)
|
